{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:09:50Z","timestamp":1758042590704,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.bone.2012.02.004","type":"journal-article","created":{"date-parts":[[2012,2,12]],"date-time":"2012-02-12T14:43:55Z","timestamp":1329057835000},"page":"1135-1140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis"],"prefix":"10.1016","volume":"50","author":[{"given":"Richard","family":"Eastell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slobodan","family":"Vukicevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine E.","family":"Ensrud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Z.","family":"LaCroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2012.02.004_bb0005","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis","volume":"362","author":"Cummings","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2012.02.004_bb0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene","volume":"13","author":"McClung","year":"2006","journal-title":"Menopause"},{"key":"10.1016\/j.bone.2012.02.004_bb0015","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bone.2009.07.089","article-title":"A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy","volume":"45","author":"Rogers","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2012.02.004_bb0020","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2012.02.004_bb0025","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","article-title":"Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk","volume":"19","author":"Sarkar","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2012.02.004_bb0030","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"Suppl 6","key":"10.1016\/j.bone.2012.02.004_bb0035","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/s001980070002","article-title":"A position paper on the use of biochemical markers of bone turnover in osteoporosis","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2012.02.004_bb0040","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","article-title":"Treatment of postmenopausal osteoporosis","volume":"338","author":"Eastell","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2012.02.004_bb0045","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bone.2007.12.218","article-title":"Establishing a reference range for bone turnover markers in young, healthy women","volume":"42","author":"Glover","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2012.02.004_bb0050","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1185\/030079904X16768","article-title":"Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis","volume":"20","author":"Sebba","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bone.2012.02.004_bb0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/00031305.1978.10479236","article-title":"Variations of box plots","volume":"32","author":"McGill","year":"1978","journal-title":"Am Stat"},{"key":"10.1016\/j.bone.2012.02.004_bb0060","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1471-0528.2002.01177.x","article-title":"The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women","volume":"109","author":"Pereda","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.bone.2012.02.004_bb0065","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1359\/jbmr.1999.14.3.471","article-title":"Variability and response of urinary resorption markers to hormone replacement therapy","volume":"14","author":"Hannon","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2012.02.004_bb0070","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1359\/jbmr.1999.14.4.602","article-title":"Monitoring alendronate therapy for osteoporosis","volume":"14","author":"Braga de Castro","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2012.02.004_bb0075","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.bone.2007.01.016","article-title":"A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density","volume":"40","author":"Saag","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2012.02.004_bb0080","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2012.02.004_bb0085","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2012.02.004_bb0090","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.283.10.1318","article-title":"Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group","volume":"283","author":"Cummings","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2012.02.004_bb0095","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","article-title":"Rapid and robust response of biochemical markers of bone formation to teriparatide therapy","volume":"45","author":"Glover","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2012.02.004_bb0100","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1359\/jbmr.090310","article-title":"Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis","volume":"24","author":"Delmas","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2012.02.004_bb0105","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2012.02.004_bb0110","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1210\/jc.2004-1091","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.bone.2012.02.004_bb0115","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s00198-010-1513-x","article-title":"Effects of calcium-fortified ice cream on markers of bone health","volume":"22","author":"Ferrar","year":"2011","journal-title":"Osteoporos Int"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328212000592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328212000592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:36:30Z","timestamp":1757612190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328212000592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S8756328212000592"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2012.02.004","relation":{},"ISSN":["8756-3282"],"issn-type":[{"type":"print","value":"8756-3282"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of 3years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2012.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}